GlassScriptPhysician profile
Caleb Matthew Lusk
NPI 1386149912
$7,337.97
in general payments reported to CMS, 2019-2025
21 companies · $1,371 in 2025
The $1,371 reported for 2025 was more than what 90% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
See the full distribution for Addiction Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $50.59 · 2023: $4,997 · 2024: $920 · 2025: $1,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,210 · Food and Beverage: $2,807 · Travel and Lodging: $1,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,210.00 |
| Food and Beverage | $2,806.74 |
| Travel and Lodging | $1,270.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $5,662.72 | 2023-2025 | Epclusa, Vemlidy |
| Abbvie INC. | $539.48 | 2023-2025 | |
| Viiv Healthcare Company | $230.61 | 2024-2025 | Apretude, Cabenuva |
| Novo Nordisk INC | $106.05 | 2024-2025 | Wegovy |
| Indivior INC. | $99.76 | 2024-2025 | Sublocade |
| Amgen INC. | $96.69 | 2024-2025 | Repatha, Otezla, Repatha |
| Braeburn INC. | $84.54 | 2023-2025 | Brixadi |
| Exact Sciences Corporation | $80.50 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi Pasteur INC. | $70.15 | 2024 | |
| Lilly USA, LLC | $67.75 | 2024-2025 | Zepbound, Mounjaro |
| Hologic Sales and Service, LLC | $49.33 | 2024-2025 | Thinprep 2000 Processor, Aptima |
| Pfizer INC. | $40.73 | 2024 | |
| Potrero Medical, INC. | $28.72 | 2021 | |
| Dexcom, INC. | $28.14 | 2024 | Dexcom G6 Transmitter |
| Sage Therapeutics, LLC | $25.47 | 2025 | Zurzuvae |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $25.47 | 2025 | Qelbree |
| Masimo Corporation | $24.40 | 2024 | Bridge |
| Astellas Pharma US INC | $23.62 | 2024 | Veozah |
| Optinose US, INC. | $21.87 | 2021 | |
| Reprise Biomedical, INC. | $19.09 | 2024 | Miro3d |
| Coopersurgical, INC. | $12.88 | 2023 | Paragard T 380a |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Lusk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.